Intelligent Financial Strategies Sells 764 Shares of Johnson & Johnson (NYSE:JNJ)

Intelligent Financial Strategies lessened its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,947 shares of the company’s stock after selling 764 shares during the quarter. Johnson & Johnson comprises 0.7% of Intelligent Financial Strategies’ investment portfolio, making the stock its 29th largest position. Intelligent Financial Strategies’ holdings in Johnson & Johnson were worth $701,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of JNJ. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after acquiring an additional 3,358,478 shares during the last quarter. GQG Partners LLC raised its holdings in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Johnson & Johnson by 37.2% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after buying an additional 1,805,632 shares in the last quarter. Swiss National Bank raised its holdings in shares of Johnson & Johnson by 14.0% during the 1st quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock valued at $2,020,868,000 after buying an additional 1,396,500 shares in the last quarter. Finally, Bridgewater Associates LP raised its holdings in shares of Johnson & Johnson by 40.3% during the 1st quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock valued at $770,065,000 after buying an additional 1,247,260 shares in the last quarter. Institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

JNJ opened at $173.46 on Thursday. The stock’s fifty day moving average is $167.44 and its two-hundred day moving average is $171.39. The company has a market capitalization of $453.51 billion, a P/E ratio of 24.16, a PEG ratio of 3.35 and a beta of 0.57. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $2.60 EPS. Analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.61%. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson announced that its board has authorized a share buyback program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Barclays initiated coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Sanford C. Bernstein decreased their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. StockNews.com began coverage on Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Citigroup decreased their price target on Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Finally, Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $184.25.

Insiders Place Their Bets

In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold 118,795 shares of company stock worth $20,230,174 in the last ninety days. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.